ClinicalTrials.gg
CompletedNCT00335153Updated Jan 16, 2015Results posted

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

A Phase 3 interventional study of Levodopa-carbidopa intestinal gel and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed at 83 sites in 16 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Dyskinesias with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyskinesias · United States.

Enrollment
9th of 82
354 · median 41
Started
2008
with 2 others
Phase 3
24 of 101
none open now
Registered
20th of 101
by date
Lead sponsor
4 of 101
AbbVie (prior sponsor, Abbott)

Among the 101 studies in Dyskinesias with a site in United States, this one is the 9th largest by enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2008, is one of 24 in phase 3, and was the 20th registered.

Dyskinesias

179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.

Browse Dyskinesias studies →

Open to participants now

8 of the 101 studies in Dyskinesias with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Dyskinesias studies recruiting now, 4 (25%) set no upper age limit and 8 (50%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Dyskinesias with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.

Read the detailed description

The study was composed of a screening period followed by 3 sequential on-treatment periods, as follows:

  • Screening Period (up to 28 days): determination of eligibility and discontinuation of antiparkinsonian disease medications other than levodopa-carbidopa immediate release (LC-oral) prior to nasojejunal (NJ) tube placement.
  • NJ Test Period (2 to 14 days): first hospitalization period, Baseline assessments, placement of NJ tube, and optimization of levodopa-carbidopa intestinal gel (LCIG) treatment via NJ tube and infusion pump (participant was hospitalized for NJ tube placement but hospitalization was not required for entire duration of LCIG treatment optimization).
  • PEG-J Period (2 to 14 days): second hospitalization period; placement of PEG-J tube; further optimization of LCIG treatment.
  • Post PEG-J Long-Term Treatment Period (Day 28 to Day 378): LCIG administration via a permanent PEG-J tube and infusion pump, with dosage adjusted according to clinical condition.
03

Conditions studied

  • Advanced Parkinson's Disease

Keywords

  • severe motor fluctuations
  • levodopa
  • levodopa/carbidopa intestinal gel
  • efficacy
  • dyskinesia
  • Parkinson's Disease
  • carbidopa
  • DUOPA
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Levodopa-responsive with severe motor fluctuations
  • Recognizable off and on state (motor fluctuations) confirmed by diary

Exclusion criteria

Exclusion Criteria:

  • Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
  • Undergone surgery for the treatment of PD
  • to levodopa (such as narrow angle glaucoma)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Levodopa-Carbidopa Intestinal Gel (LCIG)

    All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment. The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances.

    Drug: Levodopa-carbidopa intestinal gel · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: PEG tube · Device: J-tube

Interventions

  • DrugLevodopa-carbidopa intestinal gel

    Drug pages: Levodopa · Carbidopa

    Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).

  • DeviceCADD-Legacy® 1400 ambulatory infusion pump
  • DevicePEG tube

    percutaneous endoscopic gastrostomy tube

  • DeviceJ-tube

    jejunal tube

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs

    AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.

    Time frame: Screening through Day 378 + 30 days

  2. Number of Participants With Device Complications During the Nasojejunal (NJ) Test Period

    Complications of the infusion device were collected during the NJ Test period. Pump, intestinal tube, NJ tube, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.

    Time frame: NJ Test Period (from 2 to 14 days)

  3. Number of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods

    Complications of the infusion device were collected during the PEG-J Surgery and Post-PEG Long-Term Treatment periods. Pump, PEG-J, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.

    Time frame: PEG-J Surgery Period (from 2 to 14 days) through the Long Term Treatment Period (Day 28 to Day 378)

  4. Number of Participants With Potentially Clinically Significant Values for Hematology Parameters

    Potentially clinically significant values for red blood cells (RBCs), hemoglobin, and hematocrit are specified for females (f) and males (m) separately in the category rows.

    Time frame: Screening through Day 378

  5. Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

    Terms abbreviated in the table include aspartate aminotransferase (AST), upper limit of normal (ULN), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), female (f), and male (m).

    Time frame: Screening through Day 378

  6. Number of Participants With Potentially Clinically Significant Vital Sign Parameters

    Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.

    Time frame: up to 56 weeks

  7. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

    Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.

    Time frame: Screening through Day 378

  8. Number of Participants With Sleep Attacks at Baseline

    To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.

    Time frame: Baseline

  9. Number of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period

    To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.

    Time frame: During the Post-PEG Long-Term Treatment Period (Day 28 through Day 378)

  10. Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period

    The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

    Time frame: Baseline, during the Post-PEG Long-term Treatment Period (Day 28 through Day 378)

  11. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint

    The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions regarding issues with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia \[involuntary muscle movement\]).

    Time frame: Baseline, Endpoint (last Post-PEG Long-Term Period visit up to Day 378)

  12. Number of Participants With Confirmed Cases of Melanoma

    A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination or end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.

    Time frame: Screening up to Day 378

  13. Number of Participants Taking at Least 1 Concomitant Medication During the Study

    Concomitant medications include those started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.

    Time frame: Screening up to Day 378

Secondary outcomes

  1. Change From Baseline in Average Daily "Off" Time at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  2. Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  3. Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  4. Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint

    The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  5. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  6. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  7. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  8. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  9. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  10. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  11. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  12. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  13. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  14. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  15. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  16. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  17. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  18. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  19. Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint

    The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  20. Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint

    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state'.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

  21. Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint

    The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (Range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.

    Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)

07

Results

Posted Jan 16, 2015

Participant flow

Nasojejunal (NJ) Test Period
Participant flow — Nasojejunal (NJ) Test Period
MilestoneLevodopa-Carbidopa Intestinal Gel (LCIG)
Started354
Completed324
Not completed30
Withdrew: Adverse event5
Withdrew: Lack of efficacy5
Withdrew: Withdrawal by subject12
Withdrew: Administrative1
Withdrew: Protocol violation7
Post-PEG-J Long-Term Treatment Period
Participant flow — Post-PEG-J Long-Term Treatment Period
MilestoneLevodopa-Carbidopa Intestinal Gel (LCIG)
Started324
Completed272
Not completed52
Withdrew: Adverse event22
Withdrew: Lack of efficacy2
Withdrew: Withdrawal by subject13
Withdrew: Administrative13
Withdrew: Protocol violation2

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs

AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.

Time frame:
Screening through Day 378 + 30 days
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Deaths8
TE Deaths7
>=1 SAE111
>=1TESAE108
>=1 TEAE Leading to Study Termination27
>=1 TEAE323
>=1 Severe TEAE102
>=1 Possibly or Probably Treatment Related TEAE272
No TEAE31
PrimaryNumber of Participants With Device Complications During the Nasojejunal (NJ) Test Period

Complications of the infusion device were collected during the NJ Test period. Pump, intestinal tube, NJ tube, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.

Time frame:
NJ Test Period (from 2 to 14 days)
Reported as:
Number · participants
Number of Participants With Device Complications During the Nasojejunal (NJ) Test Period
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
>=1 Complication90
Pump Complication7
Intestinal Tube Complication4
NJ Tube Complication68
Other Complications25
PrimaryNumber of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods

Complications of the infusion device were collected during the PEG-J Surgery and Post-PEG Long-Term Treatment periods. Pump, PEG-J, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.

Time frame:
PEG-J Surgery Period (from 2 to 14 days) through the Long Term Treatment Period (Day 28 to Day 378)
Reported as:
Number · participants
Number of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
>=1 Complication282
Pump Complication116
Intestinal Tube Complication165
PEG-J Complication114
Stoma Complication116
Other Complication114
PrimaryNumber of Participants With Potentially Clinically Significant Values for Hematology Parameters

Potentially clinically significant values for red blood cells (RBCs), hemoglobin, and hematocrit are specified for females (f) and males (m) separately in the category rows.

Time frame:
Screening through Day 378
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
RBCs <2.0*10^12/L (f), <2.5*10^12/L (m); n=3160
Hemoglobin <90 g/L (f), <100 g/L (m); n=3164
Hematocrit <30% (f), <34% (m); n=31527
White Blood Cells <2.8*10^9/L; n=3163
White Blood Cells >16.0*10^9/L; n=3160
Neutrophils <1.2*10^9/L; n=3160
Lymphocytes <0.75*10^9/L; n=31621
Lymphocytes >80%; n=3160
Platelet Count <95*10^9/L; n=3151
Platelet Count >700*10^9/L; n=3150
Mean Corpuscular Volume <60 fL; n=3150
Mean Corpuscular Volume >120 fL; n=3150
Eosinophils >10%; n=3167
Monocytes >30%; n=3160
PrimaryNumber of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

Terms abbreviated in the table include aspartate aminotransferase (AST), upper limit of normal (ULN), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), female (f), and male (m).

Time frame:
Screening through Day 378
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
AST >3*ULN; n=3151
ALT >3*ULN; n=3150
GGT >3*ULN; n=3153
LDH >3*ULN; n=3150
Alkaline Phosphatase >400 U/L; n=3150
Total Protein <45 g/L; n=3150
Total Bilirubin >2*ULN; n=3150
Creatine Kinase >3*ULN; n=3157
Sodium <126 mmol/L; n=3152
Sodium >156 mmol/L; n=3152
Potassium <3.0 mmol/L; n=3151
Potassium >6.0 mmol/L; n=3151
Calcium <1.75 mmol/L; n=3152
Calcium >3.0 mmol/L; n=3150
BUN >10.8 mmol/L; n=774
Creatinine >177 mcmol/L; n=3153
Uric Acid >500 mcmol/L (f), >590 mcmol/L (m);n=3150
Glucose (nonfasting) <2.78 mmol/L; n=3151
Glucose (nonfasting) >16.0 mmol/L; n=3151
Cholesterol >12.9 mmol/L; n=3150
Triglycerides >5.6 mmol/L; n=3152
PrimaryNumber of Participants With Potentially Clinically Significant Vital Sign Parameters

Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.

Time frame:
up to 56 weeks
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
SuSBP >=180 and >40 mm Hg ↑ from BL; n=3244
SuSBP <=90 and >30 mm Hg ↓ from BL; n=32417
StSBP >=180 and >40 mm Hg ↑ from BL; n=3242
StSBP <=90 and >30 mm Hg ↓ from BL; n=32435
OSBP: ↓ >=30 mm Hg (Supine to Standing); n=32480
SuDBP >=105 and >30 mm Hg ↑ from BL; n=3245
SuDBP <=50 and >30 mm Hg ↓ from BL; n=32411
StDBP >=105 and >30 mm Hg ↑ from BL; n=3248
StDBP <=50 and >30 mm Hg ↓ from BL; n=32412
ODBP: ↓ >=20 mm Hg (Supine to Standing); n=32459
SuP >=120 and >30 bpm ↑ from BL; n=3240
SuP <=50 and >30 bpm ↓ from BL; n=3241
StP >=120 and >30 bpm ↑ from BL; n=3240
StP <=50 and >30 bpm ↓ from BL; n=3240
Temp >=38.3 and >1.1°C ↑ from BL; n=3222
Weight >=7% ↑ from BL; n=27225
Weight <=7% ↓ from BL; n=27279
PrimaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.

Time frame:
Screening through Day 378
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
HR <=50 and >30 bpm ↓ from BL; n=3211
HR >=120 and >30 bpm ↑ from BL; n=3211
PR Interval <120 msec; n=3216
PR Interval >220 msec; n=32126
QTcB Interval >480 msec; n=31915
QTcB Interval >60 msec ↑ from BL; n=3094
QTcF Interval >480 msec; n=3197
QTcF Interval >60 msec ↑ from BL; n=3093
PrimaryNumber of Participants With Sleep Attacks at Baseline

To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.

Time frame:
Baseline
Reported as:
Number · participants
Number of Participants With Sleep Attacks at Baseline
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Participants with >=1 Sleep Attacks7
Number of Sleep Attacks Per Participant=14
Number of Sleep Attacks Per Participant=20
Number of Sleep Attacks Per Participant=30
Number of Sleep Attacks Per Participant>32
Number of Sleep Attacks Per Participant=Missing1
Sleepiness/Drowsiness Prior to Sleep Attack4
Bad Outcome/Problem Due to Sleep Attack1
Number of Bad Outcomes/Problems=11
Number of Bad Outcomes/Problems=20
Number of Bad Outcomes/Problems=30
Number of Bad Outcomes/Problems>30
PrimaryNumber of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period

To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.

Time frame:
During the Post-PEG Long-Term Treatment Period (Day 28 through Day 378)
Reported as:
Number · participants
Number of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Participants with >=1 Sleep Attacks27
Number of Sleep Attacks Per Participant=111
Number of Sleep Attacks Per Participant=22
Number of Sleep Attacks Per Participant=35
Number of Sleep Attacks Per Participant>39
Sleepiness/Drowsiness Prior to Sleep Attack11
Bad Outcome/Problem Due to Sleep Attack2
Number of Bad Outcomes/Problems=12
Number of Bad Outcomes/Problems=20
Number of Bad Outcomes/Problems=30
Number of Bad Outcomes/Problems>30
PrimarySummary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period

The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

Time frame:
Baseline, during the Post-PEG Long-term Treatment Period (Day 28 through Day 378)
Reported as:
Number · participants
Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
BL Compulsive Buying; n=3220
BL Kleptomania; n=3220
BL Trichotillomania; n=3220
BL Intermittent Explosive Disorder; n=3220
BL Pyromania; n=3220
BL Pathological Gambling; n=3222
BL Compulsive Sexual Behavior; n=3229
PPLT Compulsive Buying; n=3183
PPLT Kleptomania; n=3180
PPLT Trichotillomania; n=3180
PPLT Intermittent Explosive Disorder; n=3180
PPLT Pyromania; n=3180
PPLT Pathological Gambling; n=3186
PPLT Compulsive Sexual Behavior; n=31811
PrimaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint

The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions regarding issues with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia \[involuntary muscle movement\]).

Time frame:
Baseline, Endpoint (last Post-PEG Long-Term Period visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline; n=3189.6 ± 8.1
Change from Baseline at Endpoint; n=317-1.7 ± 9.0
SecondaryChange From Baseline in Average Daily "Off" Time at Endpoint

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · hours
Change From Baseline in Average Daily "Off" Time at Endpoint
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline6.77 ± 2.37
Change from Baseline at Endpoint-4.44 ± 2.89
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · hours
Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline1.60 ± 2.03
Change from Baseline at Endpoint-0.36 ± 2.77
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = 0.023
SecondaryChange From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Endpoint

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · hours
Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Endpoint
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline4.83 ± 2.72
Change from Baseline at Endpoint3.86 ± 4.65
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryClinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint

The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
CGI-S Baseline4.85 ± 0.84
CGI-I at Endpoint2.10 ± 0.95
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline2.2 ± 1.9
Change from Baseline at Endpoint0.0 ± 1.8
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = 0.974
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline17.5 ± 6.7
Change from Baseline at Endpoint-4.4 ± 6.5
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline28.9 ± 13.7
Change from Baseline at Endpoint-7.4 ± 13.2
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline48.6 ± 18.9
Change from Baseline at Endpoint-11.7 ± 18.3
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline9.2 ± 2.9
Change from Baseline at Endpoint-3.5 ± 3.5
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline42.7 ± 15.0
Change from Baseline at Endpoint-6.9 ± 14.1
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline58.8 ± 22.8
Change from Baseline at Endpoint-11.2 ± 23.4
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline50.7 ± 22.3
Change from Baseline at Endpoint-8.3 ± 22.6
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline39.4 ± 21.8
Change from Baseline at Endpoint-4.2 ± 19.7
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline32.5 ± 26.0
CHange from Baseline at Endpoint-9.1 ± 22.1
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline17.2 ± 19.7
Change from Baseline at Endpoint-0.3 ± 18.9
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = 0.757
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline27.2 ± 18.6
Change from Baseline to Endpoint-4.5 ± 18.0
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline34.3 ± 20.4
Change from Baseline at Endpoint-3.9 ± 19.4
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline46.2 ± 22.9
Change from Baseline at Endpoint-5.8 ± 22.4
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint

The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline0.588 ± 0.195
Change from Baseline at Endpoint0.064 ± 0.203
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint

The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state'.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline50.2 ± 21.0
Change from Baseline at Endpoint14.0 ± 24.8
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint

The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (Range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.

Time frame:
Baseline, Endpoint (last post-baseline visit up to Day 378)
Reported as:
Mean · units on a scale
Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline27.1 ± 13.2
Change from Baseline at Endpoint0.2 ± 10.8
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · t-test, 2 sided · p = 0.824
PrimaryNumber of Participants With Confirmed Cases of Melanoma

A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination or end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.

Time frame:
Screening up to Day 378
Reported as:
Number · participants
Number of Participants With Confirmed Cases of Melanoma
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Number of Participants With Confirmed Cases of Melanoma0
PrimaryNumber of Participants Taking at Least 1 Concomitant Medication During the Study

Concomitant medications include those started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.

Time frame:
Screening up to Day 378
Reported as:
Number · participants
Number of Participants Taking at Least 1 Concomitant Medication During the Study
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Number of Participants Taking at Least 1 Concomitant Medication During the Study349

Adverse events

Collected over From Screening to the end of study or early termination of treatment, including the removal of study device (up to 54 weeks), plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levodopa-Carbidopa Intestinal Gel (LCIG)—108/354 (30.5%)278/354 (78.5%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventLevodopa-Carbidopa Intestinal Gel (LCIG)
COMPLICATION OF DEVICE INSERTIONGeneral disorders21/354
ABDOMINAL PAINGastrointestinal disorders10/354
PERITONITISGastrointestinal disorders9/354
POLYNEUROPATHYNervous system disorders9/354
PNEUMOPERITONEUMGastrointestinal disorders8/354
PARKINSON'S DISEASENervous system disorders8/354
PNEUMONIAInfections and infestations7/354
HIP FRACTUREInjury, poisoning and procedural complications6/354
DEVICE DISLOCATIONGeneral disorders5/354
WEIGHT DECREASEDInvestigations4/354
Most frequent other events
Showing 10 of 33
Most frequent other events
EventLevodopa-Carbidopa Intestinal Gel (LCIG)
COMPLICATION OF DEVICE INSERTIONGeneral disorders102/354
ABDOMINAL PAINGastrointestinal disorders92/354
PROCEDURAL PAINInjury, poisoning and procedural complications67/354
INSOMNIAPsychiatric disorders67/354
NAUSEAGastrointestinal disorders60/354
CONSTIPATIONGastrointestinal disorders55/354
EXCESSIVE GRANULATION TISSUESkin and subcutaneous tissue disorders51/354
FALLInjury, poisoning and procedural complications50/354
POSTOPERATIVE WOUND INFECTIONInfections and infestations47/354
INCISION SITE ERYTHEMAInjury, poisoning and procedural complications43/354

Baseline characteristics

Age, Continuous
Age, Continuous(years)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean64.1 ± 9.1
Age, Customized
Age, Customized(participants)Levodopa-Carbidopa Intestinal Gel (LCIG)
<65 years171
>=65 years183
Sex: Female, Male
Sex: Female, Male(Participants)Levodopa-Carbidopa Intestinal Gel (LCIG)
Female152
Male202
08

Study locations

83 sites
  • Site Reference ID/Investigator# 50065
    Birmingham, Alabama 35222, United States
  • Site Reference ID/Investigator# 50059
    Fountain Valley, California 92708, United States
  • Site Reference ID/Investigator# 50048
    Los Angeles, California 90033, United States
  • Site Reference ID/Investigator# 50076
    Oceanside, California 92056, United States
  • Site Reference ID/Investigator# 50061
    Englewood, Colorado 80113, United States
  • Site Reference ID/Investigator# 50079
    Washington, District of Columbia 20007, United States
  • Site Reference ID/Investigator# 50077
    Bradenton, Florida 34205, United States
  • Site Reference ID/Investigator# 50060
    Fort Lauderdale, Florida 33308, United States
  • Site Reference ID/Investigator# 50049
    Gainesville, Florida 32610, United States
  • Site Reference ID/Investigator# 50047
    Jacksonville, Florida 32209, United States
  • Site Reference ID/Investigator# 50068
    Port Charlotte, Florida 33890, United States
  • Site Reference ID/Investigator# 50046
    Tampa, Florida 33613, United States
  • Site Reference ID/Investigator# 50062
    Augusta, Georgia 30912, United States
  • Site Reference ID/Investigator# 50050
    Chicago, Illinois 60611, United States
  • Site Reference ID/Investigator# 50078
    Chicago, Illinois 60612, United States
  • Site Reference ID/Investigator# 50064
    Lexington, Kentucky 40536, United States
  • Site Reference ID/Investigator# 50075
    Shreveport, Louisiana 71103, United States
  • Site Reference ID/Investigator# 50080
    Baltimore, Maryland 21201, United States
  • Site Reference ID/Investigator# 50074
    Baltimore, Maryland 21287, United States
  • Site Reference ID/Investigator# 50073
    St. Louis, Missouri 63110, United States
  • Site Reference ID/Investigator# 50042
    Omaha, Nebraska 68198-2045, United States
  • Site Reference ID/Investigator# 50072
    Manhasset, New York 11030, United States
  • Site Reference ID/Investigator# 50067
    New York, New York 10029, United States
  • Site Reference ID/Investigator# 50066
    New York, New York 10032, United States
  • Site Reference ID/Investigator# 50069
    Raleigh, North Carolina 27607, United States
  • Site Reference ID/Investigator# 50063
    Winston-Salem, North Carolina 27157, United States
  • Site Reference ID/Investigator# 50043
    Cincinnati, Ohio 45267, United States
  • Site Reference ID/Investigator# 50044
    Cleveland, Ohio 44195-0001, United States
  • Site Reference ID/Investigator# 50058
    Burlington, Vermont 05401, United States
  • Site Reference ID/Investigator# 50045
    Kirkland, Washington 98034, United States
  • Site Reference ID/Investigator# 50070
    Milwaukee, Wisconsin 53226, United States
  • Site Reference ID/Investigator# 46429
    Adelaide, 5000, Australia
  • Site Reference ID/Investigator# 46427
    Heidelberg, 3084, Australia
  • Site Reference ID/Investigator# 46425
    Westmead, 2145, Australia
  • Site Reference ID/Investigator# 54545
    Edmonton, T6G 2B7, Canada
  • Site Reference ID/Investigator# 46433
    Montreal, H2L 4M1, Canada
  • Site Reference ID/Investigator# 46434
    Toronto, M5T 2S8, Canada
  • Site Reference ID/Investigator# 46436
    Brno, 65691, Czech Republic
  • Site Reference ID/Investigator# 46438
    Hradec Kralove, 500 05, Czech Republic
  • Site Reference ID/Investigator# 46435
    Pardubice, 532 03, Czech Republic
  • Site Reference ID/Investigator# 46437
    Prague 2, 128 08, Czech Republic
  • Site Reference ID/Investigator# 46439
    Prague 5, 15006, Czech Republic
  • Site Reference ID/Investigator# 48003
    Lahti, 15850, Finland
  • Site Reference ID/Investigator# 48028
    Berlin, 12200, Germany
  • Site Reference ID/Investigator# 48029
    Berlin, 13088, Germany
  • Site Reference ID/Investigator# 48036
    Freiburg, 79106, Germany
  • Site Reference ID/Investigator# 48034
    Goettingen, 37075, Germany
  • Site Reference ID/Investigator# 48022
    Hanau, 63450, Germany
  • Site Reference ID/Investigator# 48024
    Hanover, 30625, Germany
  • Site Reference ID/Investigator# 48035
    Mainz, 55131, Germany
  • Site Reference ID/Investigator# 49882
    Tel Aviv, 64239, Israel
  • Site Reference ID/Investigator# 50131
    Arcugnano, 36057, Italy
  • Site Reference ID/Investigator# 50132
    Catania, 95125, Italy
  • Site Reference ID/Investigator# 50128
    Genoa, 16132, Italy
  • Site Reference ID/Investigator# 50129
    Lido di Camaiore, 55043, Italy
  • Site Reference ID/Investigator# 50130
    Naples, 80131, Italy
  • Site Reference ID/Investigator# 50127
    Rome, 00163, Italy
  • Site Reference ID/Investigator# 50138
    Nijmegen, 6532 SZ, Netherlands
  • Site Reference ID/Investigator# 50126
    Auckland, 1010, New Zealand
  • Site Reference ID/Investigator# 50123
    Christchurch, 8011, New Zealand
  • Site Reference ID/Investigator# 50124
    Hamilton, 3204, New Zealand
  • Site Reference ID/Investigator# 50125
    Wellington, 6002, New Zealand
  • Site Reference ID/Investigator# 50140
    Lodz, 93-113, Poland
  • Site Reference ID/Investigator# 50139
    Poznan, 61-485, Poland
  • Site Reference ID/Investigator# 50136
    Almada, 2805-267, Portugal
  • Site Reference ID/Investigator# 50134
    Coimbra, 3000-075, Portugal
  • Site Reference ID/Investigator# 50135
    Lisbon, 1649-035, Portugal
  • Site Reference ID/Investigator# 50137
    Porto, 4200-319, Portugal
  • Site Reference ID/Investigator# 50143
    Kazan, 420061, Russian Federation
  • Site Reference ID/Investigator# 50141
    Moscow, 125367, Russian Federation
  • Site Reference ID/Investigator# 50145
    St. Petersburg, 193312, Russian Federation
  • Site Reference ID/Investigator# 50142
    St. Petersburg, 194044, Russian Federation
  • Site Reference ID/Investigator# 50147
    St. Petersburg, 197089, Russian Federation
  • Site Reference ID/Investigator# 50146
    St. Petersburg, 197706, Russian Federation
  • Site Reference ID/Investigator# 50154
    Barcelona, 08003, Spain
  • Site Reference ID/Investigator# 50152
    Barcelona, 08025, Spain
  • Site Reference ID/Investigator# 50202
    Barcelona, 08035, Spain
  • Site Reference ID/Investigator# 50155
    Barcelona, 08036, Spain
  • Site Reference ID/Investigator# 50153
    Madrid, 28034, Spain
  • Site Reference ID/Investigator# 50150
    Bangkok, 10330, Thailand
  • Site Reference ID/Investigator# 50151
    Bangkok, 10700, Thailand
  • Site Reference ID/Investigator# 50149
    Liverpool, L9 7LJ, United Kingdom
  • Site Reference ID/Investigator# 50148
    London, WC1N 3BG, United Kingdom
09

References and documents

Publications

  • Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14. PubMed 26777085 ↗
  • Lew MF, Slevin JT, Kruger R, Martinez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul;21(7):742-8. doi: 10.1016/j.parkreldis.2015.04.022. Epub 2015 Apr 28. PubMed 25962554 ↗
  • Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24. PubMed 25545465 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 2 years 7 months after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2006
First posted
Jun 9, 2006
Start
Jan 2008
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results delay requested
Jun 14, 2013
Results first posted
Jan 16, 2015
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00335153
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Jun 9, 2006
Start date
Jan 2008
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Jan 16, 2015
Last update
Jan 16, 2015

Study contacts

Janet Benesh
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion